Health-related quality of life, functional impairment and comorbidity in people with mild-to-moderate chronic kidney disease: a cross-sectional study - PubMed (original) (raw)

Simon Ds Fraser et al. BMJ Open. 2020.

Abstract

Objectives: To determine the associations between comorbidities, health-related quality of life (HRQoL) and functional impairment in people with mild-to-moderate chronic kidney disease (CKD) in primary care.

Design: Cross-sectional analysis at 5-year follow-up in a prospective cohort study.

Setting: Thirty-two general practitioner surgeries in England.

Participants: 1008 participants with CKD stage 3 (of 1741 people recruited at baseline in the Renal Risk in Derby study) who survived to 5 years and had complete follow-up data for HRQoL and functional status (FS).

Primary and secondary outcome measures: HRQoL assessed using the 5-level EQ-5D version (EQ-5D-5L, with domains of mobility, self-care, usual activities, pain/discomfort and anxiety/depression and index value using utility scores calculated from the English general population), and FS using the Karnofsky Performance Status scale (functional impairment defined as Karnofksy score ≤70). Comorbidity was defined by self-reported or doctor-diagnosed condition, disease-specific medication or blood result.

Results: Mean age was 75.8 years. The numbers reporting some problems in EQ-5D-5L domains were: 582 (57.7%) for mobility, 166 (16.5%) for self-care, 466 (46.2%) for usual activities, 712 (70.6%) for pain/discomfort and 319 (31.6%) for anxiety/depression. Only 191 (18.9%) reported no problems in any domain. HRQoL index values showed greater variation among those with lower FS (eg, for those with Karnofsky score of 60, the median (IQR) EQ-5D index value was 0.45 (0.24 to 0.68) compared with 0.94 (0.86 to 1) for those with Karnofsky score of 90). Overall, 234 (23.2%) had functional impairment.In multivariable logistic regression models, functional impairment was independently associated with experiencing problems for all EQ-5D-5L domains (mobility: OR 16.87 (95% CI 8.70 to 32.79, p<0.001, self-care: OR 13.08 (95% CI 8.46 to 20.22), p<0.001, usual activities: OR 8.27 (95% CI 5.43 to 12.58), p<0.001, pain/discomfort: OR 2.94 (95% CI 1.86 to 4.67), p<0.001, anxiety/depression: 3.08 (95% CI 2.23 to 4.27), p<0.001). Higher comorbidity count and obesity were independently associated with problems in mobility, self-care, usual activities and pain/discomfort: for three or more comorbidities versus none: (mobility: OR 2.10 (95% CI 1.08 to 4.10, p for trend 0.002), self-care: OR 2.64 (95% CI 0.72 to 9.67, p for trend 0.05), usual activities: OR 4.20 (95% CI 2.02 to 8.74, p for trend <0.001), pain/discomfort: OR 3.06 (95% CI 1.63 to 5.73, p for trend <0.001)), and for obese (body mass index (BMI) ≥30 kg/m2) versus BMI <25 kg/m2: (mobility: OR 2.44 (95% CI 1.61 to 3.69, p for trend <0.001), self-care: OR 1.98 (95% CI 1.06 to 3.71, p for trend 0.003), usual activities: OR 1.82 (95% CI 1.19 to 2.76, p for trend 0.019), pain/discomfort: OR 2.37 (95% CI 1.58 to 3.55, p for trend <0.001)). Female sex, lower FS and lower educational attainment were independently associated with anxiety/depression (ORs 1.60 (95% CI 1.18 to 2.16, p 0.002), 3.08 (95% CI 2.23 to 4.27, p<0.001) and 1.67 (95% CI 1.10 to 2.52, p 0.009), respectively). Older age, higher comorbidity count, albuminuria (≥30 mg/mmol vs <3 mg/mmol), lower educational attainment (no formal qualifications vs degree level) and obesity were independently associated with functional impairment (ORs 1.07 (95% CI 1.04 to 1.09, p<0.001), 2.18 (95% CI 0.80 to 5.96, p for trend <0.001), 1.74 (95% CI 0.82 to 3.68, p for trend 0.005), 2.08 (95% CI 1.26 to 3.41, p for trend <0.001) and 4.23 (95% CI 2.48 to 7.20), respectively).

Conclusions: The majority of persons with mild-to-moderate CKD reported reductions in at least one HRQoL domain, which were independently associated with comorbidities, obesity and functional impairment.

Trial registration number: National Institute for Health Research Clinical Research Portfolio Study Number 6632.

Keywords: chronic renal failure; epidemiology; primary care; public health.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Flow chart of study participants. CKD, chronic kidney disease; KDIGO, Kidney Disease Improving Global Outcomes; GP, general practitioner; QoL, quality of life.

Figure 2

Figure 2

Relationship between quality of life and functional status. (A) Functional status (by Karnofsky score) and quality of life (by EQ-5D-3L Index score). (B) Functional status (by Karnofsky score) and quality of life (by EQ-5D self-reported visual analogue scale (VAS)).

Similar articles

Cited by

References

    1. Hill NR, Fatoba ST, Oke JL, et al. . Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One 2016;11:e0158765. 10.1371/journal.pone.0158765 - DOI - PMC - PubMed
    1. Fraser SDS, Aitken G, Taal MW, et al. . Exploration of chronic kidney disease prevalence estimates using new measures of kidney function in the health survey for England. PLoS One 2015;10:e0118676. 10.1371/journal.pone.0118676 - DOI - PMC - PubMed
    1. NICE Clinical Guidelines 182 Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. London: National Institute of Health and Care Excellence, 2014. - PubMed
    1. Shardlow A, McIntyre NJ, Fluck RJ, et al. . Chronic kidney disease in primary care: outcomes after five years in a prospective cohort study. PLoS Med 2016;13:e1002128. 10.1371/journal.pmed.1002128 - DOI - PMC - PubMed
    1. Tonelli M, Wiebe N, Guthrie B, et al. . Comorbidity as a driver of adverse outcomes in people with chronic kidney disease. Kidney Int 2015;88:859–66. 10.1038/ki.2015.228 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources